• Intellia Therapeutics recently received FDA acceptance of its biologics license application for lonvoguran ziclumeran for hereditary angioedema under Priority Review, and arranged a US$400 million debt facility to support development and potential commercialization.
• The combination of Priority Review for Intellia Therapeutics’ first potential commercial product and added debt capacity could influence how the business funds late stage R&D and prepares for a potential future commercial footprint.
• We will now look at how Intellia Therapeutics’ investment narrative could evolve given Priority Review for lonvoguran ziclumeran.

Scan how Intellia Therapeutics fits alongside other gene editing and biotech plays by reviewing 34 healthcare AI…